BCM-95®, the patented turmeric extract formulation from Arjuna Natural Extracts Ltd has received a US patent (US Patent No. 8859020) for the composition for the treatment of Alzheimer’s disease comprising of curcuminoid mixture and added essential oil of turmeric. The patent also covers method of making the composition.
BCM95® has already undergone human clinical trials in patients with Alzheimer’s disease at Chinese University of Hong Kong under Prof. Larry Baum in 2008 and found to be highly beneficial in preventing further cognitive decline, disintegrating amyloid beta plaques, which on deposition in the brain is one of the major cause of development of Alzheimer’s disease, increases the vitamin E levels in the body and enhancing the curcumin levels in blood. BCM95® is also undergoing two other human clinical trials in patients with Alzheimer’s disease and subjects at risk of developing Alzheimer’s disease in Australia under the pioneering researcher Prof Ralph Martins.
“The finding will open a new world of hope to the millions battling with Alzheimer’s every day, as they will now have a natural and safe alternative to controlling Alzheimer’s” says Dr. Benny Antony Inventor of BCM-95® and Joint Managing Director of Arjuna Natural Extracts Ltd.
BCM95® has more than 23 peer reviewed publications and 12 granted and 15 ongoing patents in India, US and Japan and patent pending world over. BCM95® is also being studied for various indications including inflammation, arthritis, diabetes, depression, cancer prevention and treatment, adjunct with chemotherapy and cancer radiation, liver and gastro-intestinal diseases etc.
Nearly 36 million people worldwide suffer from Alzheimer’s or a related dementia. Only 1 in 4 people with Alzheimer’s disease have been diagnosed. Alzheimer’s and other dementia are the top cause for disabilities in later life. The cost of caring for Alzheimer’s patients in the US is estimated to be $220 billion per year. The global cost of Alzheimer’s and dementia is estimated to be $605 billion, which is equivalent to 1% of the entire world’s gross domestic product (GDP). 1 in 9 Americans over 65 has Alzheimer’s disease. One third of Americans over age 85 are afflicted with the illness. 5.2 million Americans are living with Alzheimer’s disease. Unless a cure is found, more than 13 million Americans will have the disease by 2050. Typical life expectancy after an Alzheimer’s diagnosis is 4 to 8 years.
None of the treatments available today for Alzheimer’s disease slows or stops the malfunction and death of neurons in the brain that cause Alzheimer’s symptoms and eventually make the disease fatal. The US Food and Drug Administration (FDA) have approved five medications to treat the symptoms of Alzheimer’s disease. These drugs work by increasing the amount of chemicals called neurotransmitters in the brain. Neurotransmitters help nerve cells in the brain (neurons) communicate with each other. The effectiveness of these drugs varies from person to person. While these drugs help with symptoms, they do not treat the underlying causes of Alzheimer’s.
There is a great need of a drug which can modify the disease process itself by impacting one or more of the brain changes caused by Alzheimer’s, thus stop or slow the progress of the disease. The possible targets include lowering beta amyloid, lowering beta secretase, maintain Tau protein, control inflammation, reducing insulin resistance etc. Many researchers believe successful treatment will eventually involve a cocktail of medications aimed at several targets, similar to current treatments for many cancers and AIDS.